DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.

Author(s): Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF

Affiliation(s): Departments of Medicine and Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA 94303-1334, USA. jkillen@stanford.edu

Publication date & source: 2010-09, Addiction., 105(9):1660-8.

AIMS: To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. DESIGN: Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks. SETTING: Community smoking cessation clinic. PARTICIPANTS: 243 adult smokers (> or =18 years of age; > or =10 cigarettes/day). MEASURES: Expired-air carbon monoxide confirmed 7-day point prevalence abstinence. FINDINGS: STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high 'drive' scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low 'drive scores' on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. CONCLUSION: Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low 'behavioral activation'.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017